A Glimpse of Zhongguancun Life Science Park
Zhongguancun Life Science Park, as an important support for the main platform of Beijing International Technology Innovation Center” consisting of Zhongguancun Science City, Huairou Science City, Changping Future Science City as well as Yizhuang Economic and Technological Development Zone, is a highland for the development of pharmaceutical and health industry that integrates four state-level functional zones, that is, Zhongguancun Independent Innovation Demonstration Zone, National Comprehensive Demonstration Zone for the Expansion and Opening-up of the Service Industry, Free Trade Pilot Zone, and the core area of high-level talents in Beijing. After 20 years of development, the Park has attracted multiple state-level research and development institutions to have their presence here, brought together a group of globally top scientists and hundreds of high-level talents. There are more than 600 innovative pharmaceutical enterprises and over 300 high-end talents, including 21 academicians, 4 scholars supported by the Cheung Kong Scholars Programme, 50+ personnel entitled to special allowance from the State Council, 7 academician workstations, 20+ post-doctoral research centers, 10+ national engineering research centers and key laboratories, 16 R&D centers at provincial and ministerial level, and nearly 3,000 sickbeds in the medical institutions, thus forming the trend of bringing together the whole industry chain including basic research, R&D pilot test, production and circulation, and terminal healthcare. It has been built into one of the parks with the most concentrated innovation resources in the field of life science in China, which is an innovation engine for the development of the pharmaceutical and health industry in Beijing.
300 +
High-end talents
600 +
Innovative pharmaceutical enterprises
7 +
Academician workstations
21 +
Post-doctoral research centers
10 +
Academician workstations
16
R&D centers at provincial and ministerial level
INDUSTRYGROUP
INNOVATIONPLATFORM
Beijing Zhongguancun Life Science Park Biomedicine Technology Incubation Co., Ltd. is a professional incubator specializing in the field of biomedicine. Since its establishment, it has received dozens of licensing and qualifications granted by the government. In addition, it undertakes work related to Overseas Students Pioneer Park at Beijing Zhongguancun Life Science Park and the IPR Public Service Workstation at Changping District Life Science Park, offering incubation service for more than 140 well-known startup companies in the industry, such as BeiGene, Crown Bioscience, BerryGenomics, Novogene, Sironax, Biocytogen, MyGenostics, etc.
The international incubator ATLATL, a high-end platform for the acceleration of innovation projects, which aligns with the standards of top international biopharmaceutical R&D centers, initiated by Dr. Zhu Pengcheng, focusing on key subdivisions and emerging technology fields such as cell and gene therapy, miRNA, gene editing and synthetic biology. By introducing professional research teams, it aims to build a base for double transformation in international cooperation on cutting-edge technology and the industrialization of R&D results. Recently, ATLATL, together with SEQUANTA, has set up a sequencing center to better serve customers and contribute to more unicorn companies in Beijing.
Bio2, built and officially put into operation in 2021, focusing on the needs of scientists and entrepreneurs, puts emphasis on the transformation of early results in life and health and business incubation. Relying on the combined advantages of “professional carrier platform + abundant funding channels + active interactive information base”, Bio2 provides start-up teams with ready-to-use shared office space and professional shared experimental sites. At present, nearly 30 potential projects with global leading technologies have been reserved, and 44 innovation-oriented enterprises such as Sironax, Neural Galaxy, Shuimu Biosciences, Pulmongene Ltd., and Simcere have settled here.
Changping Life Valley Marathon Digital Medical Incubator is China’s first digital medical business incubator jointly initiated by BC-TID, Zhongguancun Life Science Park and Marathon Venture Partners. With the vision of making investment for accelerating the new generation of digital medical entrepreneurs and promoting global digital medical industry-university-research innovation, the incubator will focus on the development direction of digital healthcare and smart healthcare, such as AI healthcare, medical robot, genomics, digital therapy, insurance technology, committed to making full cooperation with the world’s top parks, medical centers, scientific research institutions and other ecological partners.
2025-03-25
Pulse Point丨国内创新药企的“破晓之战”:首次盈利背后的三大突围密码
Biotalks丨质肽生物:创新研发+资本加持,GLP-1赛道的新锐力量
预计 阅 读时间:5分钟 近年来,全球糖尿病患者人数急剧上升,GLP-1受体激动剂类药物凭借其卓越的降糖效果和减重等额外益处,迅速成为医药市场的明星产品。据统计,2024年全球GLP-1药物市场规模已达到518亿美元,其中司美格鲁肽和替尔泊肽两大单品表现尤为突出,增长势头迅猛。 在国际制药巨头诺和诺德和礼来主导的GLP-1赛道中,国内创新药企也展现出强劲的竞争力。位于中关村生命科学园的 质肽生物 ...
原研创新丨刘志博团队报道靶向共价放射性药物,有望改变甲状腺髓样癌诊疗方案
近日,中关村生命科学园内科研机构 昌平实验室 刘志博团队及合作者在肿瘤学领域权威期刊 Cancer Discovery (IF = 29.7)发表题为“CTR-FAPI PET enables precision management of medullary thyroid carcinoma”的研究论文。 这项临床研究表明,靶向共价放射性药物CTR-FAPI能显著提高甲状腺髓样癌(MTC)转移...
企业资讯丨神济昌华全球首创针对渐冻症基因治疗药物获美国FDA临床研究许可
3月21日,中关村生命科学园内企业 神济昌华 自主研发的全球首款 ,适应症为肌萎缩侧索硬化(ALS)。 此次获批标志着该药物将进入I/IIa期国际多中心注册临床试验阶段,系统评估其在ALS成人患者中的安全性、耐受性及初步疗效,实现从基础研究向临床转化的关键跨越。 预计 阅 读时间:3分钟 ALS是一种累及上、下运动神经元的进行性、致死性神经退行性疾病,患者逐渐丧失运动、吞咽及呼吸等功能,中位生存期...